NORMAN, Okla. (Reuters) – Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson (JNJ.N) to a drug cartel leader as they sought to hold the drugmaker responsible for fueling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis.
The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid
Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J’s “greed” led the drugmaker to carry out a years-long marketing effort that caused “utter confusion” about the addictive painkillers’ risks.
Brad Beckworth, a lawyer for the state, in his closing argument said J&J knew opioids were harmful, yet minimized their risk of addiction, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.
“They didn’t get here from a Mexican cartel,” Beckworth said. “They got here from the pharmaceutical cartel, and the kingpin of them all is Johnson & Johnson.”
Hunter, who sued J&J in 2017, said the New Brunswick, New Jersey-based company does not dispute the crisis exists, yet “they blame everyone but themselves.”
The state urged Judge Thad Balkman, who presided over the nonjury trial for six weeks, to find J&J liable for creating a public nuisance and force it to pay up to $17 billion over 30 years to address the epidemic.
J&J denies causing the epidemic. Its lawyers have argued that its products made up a small share of opioids prescribed in Oklahoma and carried U.S. Food and Drug Administration-approved labels that warned of the addictive risks.
The case is one of around 2,000 actions by state and local governments accusing drug manufacturers of contributing to the opioid epidemic. Opioids were linked to a record 47,600 overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention.
The Oklahoma case is being closely watched by plaintiffs in other opioid lawsuits, particularly in 1,900 cases pending before a federal judge in Ohio who has been pushing for a settlement ahead of an October trial.
At trial, lawyers for Oklahoma argued that J&J, which sold the painkillers Duragesic and Nucynta, had since the 1990s marketed opioids as “safe and effective for everyday pain” while downplaying their addictive qualities.
Purdue and Teva Pharmaceutical Industries Ltd (TEVA.TA) were originally also defendants in the case. Purdue reached a $270 million settlement with the state in March and Teva settled for $85 million in June. Both deny wrongdoing.
(This story corrects name of Judge Thad Balkman in paragraph six)
Reporting by Heide Brandes; writing by Nate Raymond; editing by Noeleen Walder, Steve Orlofsky and Jonathan Oatis